{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:25Z","timestamp":1786119205514,"version":"build-2736575974"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/cco.0b013e3283253190","type":"journal-article","created":{"date-parts":[[2009,2,19]],"date-time":"2009-02-19T06:31:52Z","timestamp":1235025112000},"page":"131-137","source":"Crossref","is-referenced-by-count":32,"title":["Update on treatment of cutaneous T-cell lymphoma"],"prefix":"10.1097","volume":"21","author":[{"given":"Jennifer M","family":"Gardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine G","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Musiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H","family":"Rook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210128","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T-cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(08)60420-1","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"371","author":"Hwang","year":"2008","journal-title":"Lancet"},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R4-8-20210128","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary Syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2003.10.669","article-title":"Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms","volume":"50","author":"McGinnis","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.6004\/jnccn.2008.0030","article-title":"Non-Hodgkin's lymphomas","volume":"6","author":"Zelenetz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"R7-8-20210128","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and S\u00e9zary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0781.2007.00314.x","article-title":"Narrow-band ultraviolet therapy in early-stage mycosis fungoides: study on 20 patients","volume":"23","author":"Brazzelli","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0781.2006.00214.x","article-title":"308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides","volume":"22","author":"Kontos","year":"2006","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D398S4364W","article-title":"Treatment of mycosis fungoides using a 308-nm excimer laser: two case studies","volume":"12","author":"Meisenheimer","year":"2006","journal-title":"Dermatol Online J"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/archderm.140.10.1291","article-title":"Efficacy of the 308-nm excimer laser in the treatment of mycosis fungoides","volume":"140","author":"Passeron","year":"2004","journal-title":"Arch Dermatol"},{"issue":"3","key":"R13-8-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0151-9638(07)91813-X","article-title":"Treatment of mycosis fungoides by 308 nm excimer laser: a clinical and histological study in 10 patients]","volume":"134","author":"Passeron","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"R14-8-20210128","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-4632.2008.03177.x","article-title":"Topical 5-aminolevulinic acid photodynamic therapy for the treatment of unilesional mycosis fungoides: a report of two cases and review of the literature","volume":"47","author":"Recio","year":"2008","journal-title":"Int J Dermatol"},{"key":"R15-8-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.yadr.2006.09.008","article-title":"Photodynamic therapy","volume":"22","author":"MacCormack","year":"2006","journal-title":"Adv Dermatol"},{"key":"R16-8-20210128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1600-0781.2006.00246.x","article-title":"Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma","volume":"22","author":"Zane","year":"2006","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.det.2006.09.007","article-title":"Photodynamic therapy: other uses","volume":"25","author":"Taub","year":"2007","journal-title":"Dermatol Clin"},{"key":"R18-8-20210128","first-page":"308","article-title":"Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma","volume":"18","author":"Funk","year":"2008","journal-title":"Eur J Dermatol"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0889-8588(03)00108-4","article-title":"Total skin electron beam radiotherapy for patients who have mycosis fungoides","volume":"17","author":"Jones","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mjd.2002.123482","article-title":"Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group","volume":"47","author":"Jones","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R21-8-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2133.2006.07559.x","article-title":"Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides?","volume":"156","author":"Roberge","year":"2007","journal-title":"Br J Dermatol"},{"key":"R22-8-20210128","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2007.12.016","article-title":"Total skin electron beam therapy may be associated with improvement of peripheral blood disease in S\u00e9zary syndrome","volume":"58","author":"Introcaso","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R23-8-20210128","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.ijrobp.2007.11.039","article-title":"A prospective, open-label study of low-dose total skin electron beam therapy in mycosis fungoides","volume":"71","author":"Kamstrup","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-8-20210128","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1365-2133.2007.07901.x","article-title":"Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"156","author":"Tsirigotis","year":"2007","journal-title":"Br J Dermatol"},{"key":"R25-8-20210128","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"R26-8-20210128","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1089\/cbr.2007.0402","article-title":"Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides\/S\u00e9zary syndrome","volume":"22","author":"Avil\u00e9s","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"R27-8-20210128","first-page":"493","article-title":"Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas","volume":"8","author":"Urosevic","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"R28-8-20210128","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"R29-8-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1067\/mjd.2002.227","article-title":"A complete and durable response to denileukin diftitox in a patient with mycosis fungoides","volume":"48","author":"Carretero-Margolis","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"2 Suppl","key":"R30-8-20210128","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jaad.2007.08.033","article-title":"Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox","volume":"58","author":"Kazin","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R31-8-20210128","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/14796694.4.4.457","article-title":"Optimizing denileukin diftitox (Ontak) therapy","volume":"4","author":"Duvic","year":"2008","journal-title":"Future Oncol"},{"key":"R32-8-20210128","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/10428190701268783","article-title":"Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy","volume":"48","author":"Park","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R33-8-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ajh.21180","article-title":"Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma\/delta T-cell lymphoma and occult cirrhosis","volume":"83","author":"Avarbock","year":"2008","journal-title":"Am J Hematol"},{"key":"R34-8-20210128","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1210\/jc.2005-2839","article-title":"Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides","volume":"91","author":"Ghori","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"1 Suppl 3","key":"R35-8-20210128","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.seminoncol.2005.12.017","article-title":"Clinical experience with denileukin diftitox (ONTAK)","volume":"33","author":"Foss","year":"2006","journal-title":"Semin Oncol"},{"key":"R36-8-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3816\/CLM.2006.n.059","article-title":"Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox","volume":"7","author":"Chin","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"R37-8-20210128","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"key":"R38-8-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3816\/CLM.2008.n.005","article-title":"Cutaneous gamma\/delta T-cell lymphoma treated with radiation and denileukin diftitox","volume":"8","author":"Vidulich","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"R39-8-20210128","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3816\/CLM.2007.n.040","article-title":"Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma","volume":"7","author":"Hathaway","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"R40-8-20210128","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"R41-8-20210128","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"R42-8-20210128","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"Duvic","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"R43-8-20210128","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"key":"R45-8-20210128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/PPO.0b013e318063bd9f","article-title":"Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?","volume":"13","author":"Bates","year":"2007","journal-title":"Cancer J"},{"key":"R49-8-20210128","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1158\/0008-5472.CAN-07-1148","article-title":"A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity","volume":"67","author":"Rider","year":"2007","journal-title":"Cancer Res"},{"key":"R50-8-20210128","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"R51-8-20210128","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/biot.200800110","article-title":"Novel human antibody therapeutics: the age of the Umabs","volume":"3","author":"Ruuls","year":"2008","journal-title":"Biotechnol J"},{"key":"R52-8-20210128","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"R53-8-20210128","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.leukres.2007.11.009","article-title":"Subcutaneous alemtuzumab for Sezary syndrome in the very elderly","volume":"32","author":"Alinari","year":"2008","journal-title":"Leuk Res"},{"issue":"2 Suppl 5","key":"R54-8-20210128","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1053\/j.seminoncol.2006.01.029","article-title":"The role of alemtuzumab in the management of T-cell malignancies","volume":"33","author":"Dearden","year":"2006","journal-title":"Semin Oncol"},{"issue":"6 Suppl 5","key":"R55-8-20210128","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1053\/j.seminoncol.2007.11.006","article-title":"Mycosis fungoides: pathophysiology and emerging therapies","volume":"34","author":"Duvic","year":"2007","journal-title":"Semin Oncol"},{"key":"R56-8-20210128","first-page":"683a","article-title":"Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma [abstract]","volume":"104","author":"Duvic","year":"2004","journal-title":"Blood"},{"key":"R57-8-20210128","first-page":"613a","article-title":"Phase I-II multicenter study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma [abstract]","volume":"22","author":"Duvic","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R58-8-20210128","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides","volume":"23","author":"Molina","year":"2005","journal-title":"J Clin Oncol"},{"key":"R59-8-20210128","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaad.2007.12.021","article-title":"Stem cell transplantation in advanced cutaneous T-cell lymphoma","volume":"58","author":"Introcaso","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R60-8-20210128","first-page":"133","article-title":"Autologous bone marrow transplantation for advanced stage mycosis fungoides","volume":"7","author":"Bigler","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"R61-8-20210128","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1046\/j.1365-2141.2001.02919.x","article-title":"T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement","volume":"114","author":"Olavarria","year":"2001","journal-title":"Br J Haematol"},{"key":"R62-8-20210128","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.bmt.1704641","article-title":"Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation","volume":"34","author":"Herbert","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R63-8-20210128","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transplant"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e3283253190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:43:59Z","timestamp":1786038239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200903000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e3283253190","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}